2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
7
Venous Thrombosis
5
Venous Thromboembolism
3
Pulmonary Embolism
2
Thrombosis
1
Thromboembolism
1
Myeloproliferative Disorders
1
Hemostatic Disorders
1
Embolism
1
Interventions
Enoxaparin
4
Dalteparin
4
Tinzaparin
3
Saline Solution
3
Gemcitabine
3
Warfarin
2
Heparin, Low-Molecular-Weight
2
Heparin
2
Fondaparinux
2
Aspirin
2
130-nm albumin-bound paclitaxel
2
palbociclib
1
isoquercitrin
1
enoxaparin sodium
1
edoxaban
1
apixaban
1
alvocidib
1
Watchful Waiting
1
Tranexamic Acid
1
Sodium Chloride
1
Sodium Bicarbonate
1
Rivaroxaban
1
Pentetic Acid
1
PEGPH20
1
Nadroparin
1
Minocycline
1
Lenalidomide
1
Ketoconazole
1
Immunoenzyme Techniques
1
High-Energy Shock Waves
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thromboembolism
×
edoxaban
×
Clear all
NCT04072068
2023-05-30
EDOI
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 4
Completed
150 enrolled